TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers reported that over-expressing SRSF1, an RNA-processing gene, reduced several age-related features in human skin fibroblasts while preserving their specialized identity. In aged mice, SRSF1 was linked to a 14% lifespan extension, but the supplied report does not establish safety or effectiveness in people.
Researchers report that increasing activity of the gene SRSF1 reduced several age-related features in human skin cells without turning them into a different cell type, and extended lifespan by 14% in aged mice. The Nature Aging study points to a possible route toward gene therapies that seek to rejuvenate tissues while preserving cell identity, but it does not show that the approach is safe or effective in humans.
The team first developed a machine-learning predictor of transcriptomic age, using patterns of gene expression in human skin fibroblasts. Fibroblasts are connective-tissue cells; the researchers trained the model on profiles spanning multiple aging processes and ages. They tested it on cells from donors aged 55, 65 and 79, and report that it detected age-score shifts after experimental interventions, including exposure to Yamanaka factors.
Using that score as a screening measure, the researchers tested a focused collection of genes thought to affect aging. SRSF1, which encodes an RNA-processing factor, ranked highest in the screen. When over-expressed in older fibroblast cell lines, it lowered measures associated with cellular senescence, proteostatic stress and inflammation, according to the study. The report describes the cells as retaining their specialized identity; it does not provide evidence here that the intervention restores every aspect of youthful function.
The researchers also delivered SRSF1 to aged mice. The gene primarily accumulated in the liver, and the team reported a reduced rate of aging and a 14% extension in lifespan. That result is from an animal study, not a clinical trial. The supplied report does not specify the number of mice, the dosing details, or how the lifespan result varied across animals, so those details cannot be assessed from the available material.
A Candidate Beyond Yamanaka Factors
The work addresses a central challenge in experimental rejuvenation: researchers want to make aging cells behave more youthfully without erasing the features that let them perform their normal jobs. Full reprogramming with Yamanaka factors can return mature cells to a pluripotent state, but that loss of specialization and concerns about cancer risk complicate therapeutic use. The study presents SRSF1 as a different candidate, with reported effects on aging-related measures while fibroblasts remained fibroblasts.
The proposed age predictor also offers a potential screening tool. Rather than relying only on an epigenetic clock, which the researchers describe as costly and difficult to scale for this purpose, the model reads gene-expression patterns as a measure of cell state. If validated more broadly, such a method could help researchers compare interventions and prioritize candidates before animal or clinical testing.
For readers, the distinction between a promising biological result and an available treatment is key. The reported lifespan change occurred in mice, while the human-cell experiments involved lab-grown skin cells. The findings support further research; they do not establish that SRSF1 can extend human life or treat age-related disease.
As an affiliate, we earn on qualifying purchases.
From Cell Reprogramming to SRSF1
In 2006, Shinya Yamanaka showed that a set of four genes could reprogram many mature cells into an undifferentiated, pluripotent state. Later research found that short bursts of these factors could partly reverse age-associated features while retaining some cell functions. That approach helped establish the idea that aging cells may retain capacity for rejuvenation, but it also raised concerns about loss of cell identity and cancer formation.
The study team, led by George Church of Harvard Medical School and involving the Wyss Institute at Harvard and CIC bioGUNE-BRTA in Spain, sought genes that might affect aging without that degree of reprogramming. Its strategy combined a cell-age model with a targeted gene screen, then tested the leading candidate in cells and mice. The result is a preclinical research finding, not evidence of a therapy ready for patients.
“In reprogramming, there is a fundamental tradeoff between rejuvenation and cell identity; achieving one without losing the other requires walking a fine line.”
— Alex Plesa, study co-first author
anti-aging skin fibroblast supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Human Safety and Efficacy Remain Unknown
The study as described does not establish whether SRSF1 can safely rejuvenate tissues in people, how long any effects might last, or what dose and delivery method would be appropriate. The report notes that the gene primarily accumulated in the liver of mice, but does not provide enough detail here to determine how delivery might be controlled across different organs or what unintended effects could occur.
It is also unclear how broadly the findings apply beyond skin fibroblasts and the animal model. The reported reduction in several aging-related measures does not by itself prove improved function across tissues, prevention of age-related illness, or longer healthy lifespan in humans. The 14% lifespan extension is a study finding in aged mice; the supplied material does not give its statistical details or the study’s full experimental limitations.
lifespan extension supplements for mice
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Further Testing Before Human Use
The next research steps are to test how reliably SRSF1 affects aging measures across cell types and tissues, examine how its effects change with dose and duration, and assess safety, including the risk of disrupting normal cell functions. The researchers also would need to establish a dependable delivery approach and determine whether the observed changes translate into meaningful improvements in tissue health.
No human trial or clinical timetable is described in the supplied report. For now, the work remains a preclinical candidate and screening platform. The key next question is whether the cell and mouse findings can be reproduced and developed without harmful effects before any assessment in people.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the researchers find?
They reported that over-expressing SRSF1 reduced several aging-associated features in human skin fibroblasts and extended lifespan by 14% in aged mice.
Does the study show that SRSF1 reverses aging in people?
No. The supplied report describes experiments in lab-grown human skin cells and aged mice, not a human trial. It does not show that SRSF1 extends human lifespan or improves health in patients.
How did the team identify SRSF1?
The researchers built a machine-learning predictor based on gene-expression patterns, then used it to screen a focused collection of genes for effects on the age score in older fibroblasts.
Why is preserving cell identity important?
Mature cells have specialized functions. Reprogramming methods can make cells less specialized, and the researchers cite concerns about identity loss and cancer risk with Yamanaka factors. The study tested whether SRSF1 could affect aging measures while retaining fibroblast identity.
What remains unknown?
Safety, effective dosing, delivery to specific tissues, durability of effects and relevance to human health are not established by the findings described. The reported lifespan result is limited to aged mice.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
